Le Lézard
Classified in: Health, Science and technology
Subject: Survey

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global neurofibromatosis treatment drugs market is estimated to be valued at US$ 8,801.0 million in 2020 and is expected to exhibit a CAGR of 13.4% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Neurofibromatosis Treatment Drugs Market:

Alliances among key player such as joint forum, site partnerships for clinical studies are facilitating the market growth. On April 30, 2020, Massachusetts General Hospital U.S. and Pfizer collaboratively initiated phase 2 clinical study on tanezumab in subjects with moderate to severe pain due to Schwannomatosis. (Schwannomatosis is an extremely rare genetic disorder closely related to the more-common disorder neurofibromatosis (NF)).

The pediatric population is one of the most vulnerable population groups for neurofibromatosis, and other rare diseases that result in substantial economic and productivity loss across the world. Increasing demand for new treatments has created an opportunity for player to develop novel treatment approaches. Moreover, approvals of neurofibromatosis treatment drugs are expected to contribute to the growth of the global neurofibromatosis treatment drugs market. For instance, in April 2020, AstraZeneca Pharmaceuticals received the U.S. FDA's approval for its Koselugo (selumetinib) for treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1).

Increasing focus of pharma and biotech companies on research and development of novel treatment drugs for neurofibromatosis is expected to drive the global neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete on April 30, 2022.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4188

Key Market Takeaways:

The global neurofibromatosis treatment drugs market is expected to exhibit a CAGR of 13.4% during the forecast period, as increasing trend of outsourcing the drug development for use by pharmaceutical and biotech companies to clinical research organization provides independent product development solutions and services for the pharmaceutical, biotechnology, and medical device industries.

Among regions, Asia Pacific is expected to witness significant growth in the global neurofibromatosis treatment drugs market during the forecast period owing to presence of major players such as Hutchison Medipharma Limited (Chi- Med). In January 2020, Hutchison Medipharma Limited announced that its SANET-p Study, a phase III study for Surufatinib achieved its primary end-point in the treatment of low-grade or intermediate-grade advanced pancreatic neuroendocrine tumor patients. This positive result for Surufatinib (SANET-p) study is expected to introduce prominent treatment options for the patients with pancreatic neuroendocrine tumor. Patients with neurofibromatosis-1 (NF-1) sometime develop neuroendocrine tumors (NET).

Key player operating in the global neurofibromatosis treatment drugs market is AstraZeneca Plc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4188

Market Segmentation:

Related Market Intelligence Report:

Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 ? 2027

Read more: https://www.coherentmarketinsights.com/market-insight/mucopolysaccharidosis-treatment-market-4184

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

These press releases may also interest you

at 20:39
Trusted health and lifestyle expert, Dr. Yael Varnado gives advice for fall health and wellness. Dr. V is a practicing physician. STAYING WELL Taking better care of ourselves can be as easy as swapping out a light bulb. Choosing the right lighting...

at 20:10
Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of...

at 20:00
Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, today announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma") as well as...

at 19:35
EdiGene, Inc. ( "Company", or "EdiGene"), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted for review the Company's Investigational New Drug (IND) application for ET-01,...

at 19:32
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its new VITROS® SARS-CoV-2 Antigen test, designed to detect active SARS-CoV-2 infection, achieved CE Mark for distribution throughout the EU. The company also...

at 19:23
CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside of Greater China Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) to...

News published on 25 september 2020 at 10:10 and distributed by: